摘要
目的研究乳腺癌组织中拓扑异构酶Ⅱα(TOPOⅡα)和尿激酶型纤溶酶原激活物(UPA)表达的相关性及临床意义。方法采用免疫组织化学SP法,检测69例乳腺癌组织中TOPOⅡα及UPA的表达情况。结果乳腺癌中TOPOⅡα的阳性率为42.03%(29/69),UPA的阳性率为59.42%(41/69),二者的表达成高度正相关(r=0.9984)。TOPOⅡα在无淋巴结转移组的阳性表达率明显高于有淋巴结转移组(P<0.05),UPA在无淋巴结转移组的阳性表达率也明显高于有淋巴结转移组(P<0.05),二者与乳腺癌的年龄、部位无明显相关性。结论 TOPOⅡα和UPA在乳腺癌中表达与淋巴结转移有相关性。检测TOPOⅡα和UPA对临床选择治疗方法有指导意义。
Objective To study the expression and clinical significance of topoisomerseⅡα（TOPOⅡα） and urokinase type plasmivnogen activator（UPA） in breast cancer.Methods The expressions of TOPOⅡα and UPA were examined with streptavidin-perosidase immunohistochemistry method in 69 cases of breast cancer.Results The positive rates of TOPOⅡα and UPA were 42.03%（29/69） and 59.42%（41/69） in breast cancer respectively.TOPOⅡα had a high relation with UPA in breast cancer（r = 0.9984）.The positive rates of TOPOⅡα in non-lymph metastasis group was higher than that in lymph metastasis（P〈0.05）.The positive rates of UPA in non-lymph metastasis group was higher than that in lymph metastasis too（P〈0.05）,but its pathological type and breast cancer pathological type relevance was not obvious（P〈0.05）.Conclusion The expression of TOPOⅡα and UPA have relation with breast cancer metastasis.It is directing significance of detection of TOPOⅡα and UPA on clinical selection treatment.
出处
《中国医药导报》
CAS
2012年第10期33-34,共2页
China Medical Herald
基金
河北省张家口市科技局项目(项目编号:0801021D)
